DocMorris AG
0RRB.L
London Stock Exchange9.09
CHF
-0.16
- -
DocMorris AG
0RRB.L
(London Stock Exchange)
Recent
price
9.09
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- DocMorris AG is a leading European online pharmacy and digital healthcare company with a strong presence in Germany, the Netherlands, Spain, France, Portugal, and Switzerland. The company’s core offerings include prescription medicines (Rx), over-the-counter (OTC) medicines, consumer health products, beauty and personal care items, nutritional supplements, painkillers, first aid products, and other pharmaceutical goods. It operates an extensive e-commerce pharmacy platform complemented by a marketplace model that partners with over 1,500 pharmacies and sellers across Europe to expand product assortment and ensure fast delivery. Additionally, DocMorris provides professional healthcare services such as telemedicine consultations, digital prescription management, automated prescribing, direct billing solutions, and pharmaceutical advice targeted at doctors, pharmacies, insurers, and health institutions. Founded in 1993 and headquartered in Frauenfeld, Switzerland, the company evolved from its former identity as Zur Rose Group, adopting the DocMorris AG name in May 2023 following a strategic divestment of its Swiss business to Migros subsidiary Medbase. In recent years, DocMorris has completed several acquisitions including leading online pharmacies like medpex and Eurapon, and telemedicine provider TeleClinic, expanding its integrated digital health ecosystem. The firm has also innovated in e-prescription services with a fully digital redemption channel through the electronic health card, recently launched CardLink solution via its app, enabling next-day delivery and subscription management of prescriptions predominantly in Germany. In 2024, DocMorris reported revenues of CHF 1,085 million and served over 10 million active customers with roughly 1,600 employees across its operational regions. Recent significant developments include the successful transition and growth of its electronic prescription business in Germany, recording double-digit growth in OTC sales and a rising market share for e-prescriptions, despite temporary declines from mandate-related impacts. The company completed its break-even program in 2024 by closing the Halle site and discontinuing the Zur Rose brand. It also initiated a CHF 200 million capital increase to finance anticipated medium-term growth, particularly in prescription medicines. DocMorris continues to invest in the digitalization of healthcare, enhancing customer experience with telemedical care and streamlining supply chain logistics by consolidating operations such as capacity expansion at its Heerlen location and closure of the Bremen logistics site to optimize efficiency. In summary, DocMorris AG operates as a comprehensive digital health service provider encompassing online pharmacy retail, marketplace services, and professional healthcare solutions across multiple European markets. It specializes in prescription and non-prescription pharmaceutical products, telemedicine, and health services, leveraging technology to facilitate seamless health management for patients, healthcare professionals, and partners. Its recent strategic shifts include rebranding, operational consolidation, digital innovation in e-prescriptions, and capital expansion to support its growth trajectory within the evolving pharmaceutical and telehealth landscape. The company is listed on the SIX Swiss Exchange under the ticker DOCM.